BMC Cancer, 12:292. BioMed Central BMC Cancer, Vol 12, Iss 1, p 292 (2012) BMC Cancer, 12 BMC Cancer BMC cancer, 12. BioMed Central Mekenkamp, L J M, de Nooy-van Tol, J, Dijkstra, J R, de Krijger, I, Vink-Borger, M E, van Vliet, S, Teerenstra, S, Kamping, E, Verwiel, E, Koopman, M, Meijer, G A, van Krieken, J H J M, Kuiper, R, Punt, C J A & Nagtegaal, I D 2012, ' Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients ', BMC Cancer, vol. 12, 292 . https://doi.org/10.1186/1471-2407-12-292